Ipamorelin Dosage: Growth Hormone Research Protocol

Read this first

Dosage and protocol figures on this page are reproduced only from the matching PeptideDosages.com protocol. The 3 ml table is arithmetic based on those source amounts and the listed vial sizes. Educational research only — not instructions or medical advice.

Dosage chart

The dosage amounts and schedules below come only from PeptideDosages.com. Syringe-unit figures are mathematical conversions of those source amounts using exactly 3 ml of bacteriostatic water. Educational reference only — not instructions or medical advice.

Ipamorelin · 10 mg Vial

Ipamorelin is dosed at 100 mcg–250 mcg daily via subcutaneous injection in educational protocols.

Typical daily range: 100–300 mcg once daily (gradual titration recommended).

Standard / Gradual Approach

Week	Daily Dose (mcg)
Weeks 1–2	100 mcg
Weeks 3–4	150 mcg
Weeks 5–8	200 mcg
Weeks 9–12	250 mcg

3 ml conversion

Select vial strength

5 mg + 3 ml = 1.67 mg/ml. Choose your vial strength to update the units below.

Source dose	U-100 syringe
100 mcg	6.0 units
150 mcg	9.0 units
200 mcg	12 units
250 mcg	15 units

Mixing note: growth-hormone secretagogues like Ipamorelin are commonly reconstituted with 0.5 ml of acetic acid solution topped up with 2.5 ml of bacteriostatic water (3 ml total). Educational reference only — not instructions.

Source chart on peptidedosages.com

Other growth hormone compounds

MGFSplice variant of IGF-1 produced by mechanically loaded muscle MK-677Orally active ghrelin mimetic (non-peptide)PEG-MGFPolyethylene-glycol conjugated MGF analogue SermorelinGHRH (1-29) analogue TesamorelinStabilised GHRH analogue Tesamorelin + IpamorelinStabilised GHRH analogue + selective secretagogue blend

All research protocols

Ipamorelin: research background

What Ipamorelin Is

Ipamorelin is a pentapeptide, meaning it is a chain of five amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2) (PMID 9849822). It is described as a potent growth hormone (GH) secretagogue, a substance that stimulates the release of growth hormone (PMID 9849822, PMID 41490200). Within the class of peptides, it falls into a unique pharmacological niche, acting between small-molecule drugs and large proteins (PMID 41966639).

How It Is Thought to Work

Ipamorelin, like other growth hormone secretagogues, activates IGF-1 signaling (Insulin-like Growth Factor 1) and satellite cell repair (PMID 41490200). It stimulates GH release via a specific receptor, known as a GHRP-like receptor (PMID 9849822). Unlike some other GH secretagogues, ipamorelin did not significantly increase plasma levels of ACTH (adrenocorticotropic hormone) or cortisol in swine, even at doses over 200 times higher than its effective dose for GH release (PMID 9849822). This suggests a selectivity for GH release (PMID 9849822).

What Laboratory and Animal Studies Report

In vitro, ipamorelin released GH from primary rat pituitary cells with potency and efficacy similar to another secretagogue, GHRP-6 (PMID 9849822). In anesthetized rats, it released GH with comparable potency and efficacy to GHRP-6 (PMID 9849822). In conscious swine, ipamorelin also released GH, showing similar effectiveness to GHRP-6 (PMID 9849822). When combined with CJC-1295, ipamorelin showed significantly improved maximum tetanic tension in murine (mouse) models with glucocorticoid-induced muscle loss (PMID 41476424). Many unapproved peptides, including ipamorelin, have shown favorable tissue repair and metabolic outcomes in various animal models (PMID 41966639, PMID 42578445).

Human Evidence So Far

As of the provided abstracts, there is a current lack of clinical trials specifically for ipamorelin (PMID 41490200). While preclinical studies show promise, human orthopaedic data is lacking (PMID 41476424). Overall, human clinical studies for emerging peptides like ipamorelin are limited, with most lacking robust controls or rigorous study designs (PMID 42578445). The claimed benefits in humans for musculoskeletal recovery and performance remain largely unsubstantiated by current human trials (PMID 42578445).

Open Questions and Limitations

Despite its potential, ipamorelin, like many other peptides, is marketed directly to patients largely outside of regulatory oversight (PMID 41966639). While preclinical studies are promising, human safety data for such unapproved peptides are scarce, and there is potential for serious harm (PMID 41966639). The extent of its use in the general population is unknown, and potential risks like cardiovascular strain, insulin resistance, and dyslipidemia have been highlighted for performance-enhancing peptides generally (PMID 41880199). Future rigorous validation through well-designed clinical trials is needed to establish safety and efficacy (PMID 42021992, PMID 42021992).

Studies cited in this section

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026 (PMID 41490200)
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. — The American journal of sports medicine, 2026 (PMID 41476424)
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. — Sports medicine (Auckland, N.Z.), 2026 (PMID 41966639)
Ipamorelin, the first selective growth hormone secretagogue. — European journal of endocrinology, 1998 (PMID 9849822)
Peptide Supplements and Their Therapeutic Applications in Sports Medicine. — The American journal of sports medicine, 2026 (PMID 42578445)
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. — Frontiers in aging, 2026 (PMID 42021992)
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. — The Journal of sports medicine and physical fitness, 2026 (PMID 41880199)

Summarised from the PubMed abstracts listed above. Educational reference only — not medical advice or instructions.

Nearby in the protocol A–Z

Continue your research

Three steps most readers take from here

View verified suppliers

1 · Read the background
Mechanism, half-life and what the published Ipamorelin literature actually shows.
Ipamorelin research brief
2 · Plan the bench work
Work out reconstitution volumes and concentrations before ordering anything, so you buy the vial size your protocol actually needs.
Reconstitution calculator
3 · Check the paperwork
Only use material released with a lot-matched third-party certificate of analysis. Suppliers we have checked publish theirs openly.
Ipamorelin reference page How we verify suppliers

We are an independent publication: we sell nothing, hold no stock and take no payment. Outbound supplier links are marked nofollow/sponsored. Compounds discussed are laboratory research reagents, not medicines.

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.

Ipamorelin dosage protocol